Use of the term "urethral suppository" in a consumer print ad for the transurethral alprostadil erectile dysfunction therapy represents an "unfamiliar medical term," FDA maintains in April 1 letter to firm. "The majority of men exposed to this advertisement will not understand that Muse is a suppository designed to be inserted in the opening of a man's penis," FDA explains. Muse TV broadcast ads were the subject of a February NOV letter from FDA for inadequate information on side effects, including hypotension ("The Pink Sheet" March 9, p. 12)
You may also be interested in...
A television advertisement for Vivus' erectile dysfunction urethral suppository Muse (alprostadil) fails to disclose the route of administration, an FDA warning letter says
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011